Summary
Isosorbide-5-mononitrate (IS-5-MN), the main metabolite of isosorbide dinitrate shows antianginal efficacy and is being used increasingly as a drug for practical therapy. In conscious dogs we therefore measured the effects of increasing doses of IS-5-MN on hemodynamic parameters and the diameter of the circumflex artery. We found a dose dependent reduction of the mean right atrial pressure, the systolic blood pressure and a dilatation of the circumflex artery. For all three parameters threshold dosages were between 0.01 and 0.03 mg/kg. On the contrary peripheral and coronary resistance did not change at doses ≤0.3 mg/kg. The heart rate was significantly increased only at doses above 1 mg/kg and the diastolic blood pressure also showed a tendency to fall only at doses above 1 mg/kg. Cardiac output and coronary flow were not significantly altered over the entire dose range investigated, with the exception of a transient rise in coronary blood flow after the injection of 2.5 mg/kg IS-5-MN.
From our results we can deduce that in the low dose range reduction of preload and dilatation of large arteries are the main effects of IS-5-MN. In contrast, no reduction of the coronary or peripheral resistance is to be expected.
Similar content being viewed by others
References
Abshagen U (1985) Organic nitrates. In: Abshagen U (ed) Clinical pharmacology of antianginal drugs, vol 76, Handbook of experimental pharmacology. Springer, Berlin Heidelberg New York Tokyo, pp 287–364
Bassenge E, Holtz J, Kolin A, Graser G (1981a) Observations on coronary conductance artery vasomotion by induction angiometry and ultrasonic dimension technique. Basic Res Cardiol 76:524–529
Bassenge E, Holtz J, Kinadeter H, Kolin A (1981b) Threshold dosages of nitroglycerin for coronary artery dilatation, afterload reduction, and venous pooling in conscious dogs. In: Lichtlen PR, Engel HJ, Schrey A, Swan HJC (eds) Nitrates III. Springer, Berlin Heidelberg New York, pp 238–250
Bassenge E, Stewart DJ (1986) Effects of nitrates in various vascular sections and regions. Z Kardiol (in press)
Chasseaud LF, Taylor T (1981) Pharmacokinetics of isosorbide mononitrates in human subjects. In: Lichtlen PR, Engel HJ, Schrey A, Swan HJC (eds) Nitrates III. Springer, Berlin Heidelberg New York, pp 47–53
Jansen W, Tauchert M, Osterspey A, Hilger HH (1985) Comparison of the hemodynamic effects of various doses of isosorbide-5-mononitrate following single dose and long-term administration in patients with coronary heart disease. In: Cohn JN, Rittinghausen R (eds) Mononitrates. Springer, Berlin Heidelberg New York Tokyo, pp 171–187
Needleman P (1975) Biotransformation of organic nitrates. In: Needleman P (ed) Handbook of experimental pharmacology, vol 40. Springer, Berlin Heidelberg New York, pp 57–95
Saeed M, Holtz J, Sommer O, Kühne G, Bassenge E (1984) Betaadrenergic activation of the renin-angiotensin system following alpha2-, alpha1-, or nonselective alpha-blockade in conscious dogs: No relation to the changes in blood pressure. J Cardiovasc Pharmacol 6:683–692
Sponer G, Kühnle H-F, Strein K, Bartsch W, Endele R, Dietmann K (1983) Pharmacokinetic aspects of isosorbide-5-mononitrate in dogs. J Pharmacol Exp Ther 228:235–239
Strein K, Sponer G, Bartsch W, Müller-Beckmann B, Dietmann K (1984) Electrocardiographic analysis of the effects of isosorbide-5-mononitrate on regional myocardial ischemia in conscious dogs. J Pharmacol Exp Ther 229:787–792
Strein K, Müller-Beckmann B, Voss E, Bartsch W (1985a) Dose-dependent effects of some vasodilating drugs on pre- and afterload in conscious dogs. Naunyn-Schmiedeberg's Arch Pharmacol (Suppl) 329: R58, Abstr 232
Tauchert M, Jansen W, Osterspey A, Fuchs M, Hombach V, Hilger HH (1983) Dose dependence of tolerance during treatment with mononitrates. Z Kardiol 72: (Suppl 3) 218–228
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bassenge, E., Strein, K. Dose-dependent effects of isosorbide-5-mononitrate on the venous arterial and coronary arterial system of conscious dogs. Naunyn-Schmiedeberg's Arch. Pharmacol. 334, 100–104 (1986). https://doi.org/10.1007/BF00498746
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00498746